Type 2 diabetes mellitus
Conditions
Interventions
None listed
Sponsors
Toho University Omori Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All adult patients with diabetes who received a prescription for once-weekly injectable semaglutide and whose dose was escalated from 0.5 mg to 1.0 mg during the study interval.
Exclusion criteria
Exclusion criteria: Exclusion criteria were as follows: diagnosis of type 1 diabetes mellitus, excessive alcohol consumption(defined as a mean daily intake of pure alcohol >60 g for men or >30 g for women), diagnosis of dementia, pregnancy during the data collection period, hospitalization for one week or longer for glycemic management during the data collection period, end-stage renal disease requiring maintenance dialysis at baseline, initiation of once-weekly semaglutide at another institution, insufficient follow-up time to obtain 24-week data (defined as having initiated the 1.0 mg dose less than 18 weeks prior to March 10, 2025), clinically significant non-adherence as judged by the treating physician, and patients deemed unsuitable for participation by the attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Within-patient change in HbA1c 24 weeks after the initial prescription of 1mg semaglutide. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in metabolic parameters and the incidence of adverse events. | — |
Countries
Japan
Contacts
Public ContactGenki Sato
Toho University Omori Medical Center Diabetes, Metabolism and Endocrinology Center
Outcome results
None listed